Human protein produced in CHO-cells can save donor blood

Tuesday 26 Mar 19
by Anne Lykke, Anders Mønsted


Bjørn Gunnar Voldborg
Director Cell Line and Protein Production Facility
DTU Bioengineering
+45 21 12 61 91

Researchers from DTU Biosustain have successfully produced mammalian cell lines (CHO) that can produce 1.2 g/L recombinant Alpha-1-antitrypsin proteins with human glycosylation profiles. This work can lead to better treatment of the genetic disease Alpha-1 antitrypsin deficiency and avoid dependency of blood donors.

Alpha-1-antitrypsin is a protein produced by the liver. The protein gets secreted to the blood stream, where it circulates the body to protect the lungs.

However, some people are born with genetic disorders that hinders production of this protein. These patients can suffer from decreased lung function, liver diseases and shortness of breath.

In the US and other countries, the disorder is currently treated with fractions of human plasma containing Alpha-1-antitrypsin. Treatment requires an infusion of approximately four grams of protein pr. week. To obtain this dose, blood from 900 donors is needed, and the treatment amounts to approximately 100,000 Dollars a year pr. patient.

Now, a group of researchers from The Novo Nordisk Foundation Center for Biosustainability at Technical University of Denmark has found a way to produce this protein in mammalian cells.

“The current production of Alpha-1-antitrypsin from blood requires a constant and large supply of blood from donors. With a recombinant alternative, you can both formulate the product, concentrate the protein, purify it, and avoid dependency of blood donors – so we would be able to ensure security of supply,” says Bjørn Voldborg, Director of CHO Cell Line Development at The Novo Nordisk Foundation Center for Biosustainability.

CHO-cells can produce over 1 gram
"With a recombinant alternative, you can both formulate the product, concentrate the protein, purify it, and avoid dependency of blood donors "
Bjørn Voldborg, Director at Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain)

The researchers have successfully produced Alpha-1-antitrypsin in CHO cells – one of the most deployed cell lines for production of human therapeutic proteins. Normally, the CHO glycosylation profile of Alpha-1-antitrypsin is quite different from the human counterpart. The human version of Alpha-1-antitrypsin has a very specific sugar-structure, whereas if produced in CHO cells exhibits a variety of sugars, which renders the protein ineffective in the human body.

The researchers obtained this glycosylation profile by introducing a human gene encoding an enzyme capable of decorating the sugar backbones on the Alpha-1-antitrypsin proteins with the correct human moieties. Furthermore, they removed a number of the CHO cells natural glycosylation genes using CRISPR-Cas9.

This effort resulted in a cell line capable of producing over 1.2 grams pr. liter of cultured CHO cells, thereby making it possible to produce Alpha-1-antitrypsin from CHO cells at a scale that can eliminate the need for human donors in the future.

“This is definitely a step in the right direction when we are looking at production of glycosylated therapeutic proteins. We are quite confident that we can improve the yield even further, which will make this product commercially interesting to the pharma industry,” says Bjørn Voldborg.

Today, CHO-cells with the best yield produce around 10-12 g/L of monoclonal antibodies. Hence, this Alpha1-antitrypsin producing cell line is still only producing around 10 % of this known maximum. One of the next steps is, therefore, to improve the yield even further.

Great perspectives going forward

The natural Alpha-1-antitrypsin is being degraded rather quickly in the body. Going forward, researchers wants to make the recombinant proteins more stable, so Alpha1-antitrypsin deficiency patients would need fewer injections. Hence, this new knowledge about glycosylation profiles opens a new window for optimizing human proteins to improve their stability and function.

“Our hope is to optimize stability and to become so good at designing glycans, that researchers and companies can order glycan structures on any protein from us. This will accelerate the production of new glycosylated proteins for therapeutic use,” says Bjørn Voldborg.

Several pharma companies have already shown interest in this research. The research has been published in Metabolic Engineering.

Alpha1-antitrypsin deficiency

Alpha1-antitrypsin deficiency (AATD) is affecting 1 per 3000-5000 individuals, according to Medscape. Some doctors suspect a rather great under-diagnosing, because some doctors may mistake the symptoms being caused by Chronic Obstructive Pulmonary Disease (COPD). Also, correct diagnosing requires comprehensive testing of Alpha1-antitrypsin in the blood to detect this deficiency.

By 2011, three products for AATD treatment were approved by the FDA, the United States’ agency regulating medicinal products. ‘Augmentation therapy’ is authorised in the EU, but it is only readily available in a few Member States such as Germany (since 1989), Austria, France, Italy, Spain and Portugal.

News and filters

Get updated on news that match your filter.